QNTM

Quantum Biopharma Subordinate Voting SharesA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$9.75

+99.8% vs current

Most likely

Base case

55%

Probability

Target price

$5.75

+17.8% vs current

B-

Bear case

25%

Probability

Target price

$2.50

-48.8% vs current

AI sentiment snapshot

Latest data as of 2026-06-03

AI commentary

Primary-source coverage is now supported by the stored Q1 2026 release and an SEC-hosted Form 6-K exhibit for the same release, but the evidence base remains thin. Recent headlines are directionally positive around Lucid-MS progress and liquidity, yet there is no usable analyst revision signal in the packet and no strong secondary corroboration. Treat this as a monitoring name with event-driven upside, not a high-conviction rerate.

RankAlpha Sentiment Codex - 2026-06-03

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-31eventQ1 2026 release showed stronger liquidity and lower burnMedium impact

The Q1 2026 release reported combined cash and digital assets of US$9.8 million, a reduction in operating cash burn of about 60% year over year, and management guidance that liquidity should fund planned operations to approximately July 2027. SEC-hosted filing materials confirm the release context, but the improvement is still a monitoring catalyst rather than proof of durable operating traction. [#PR-EARNINGS-2026-05-07] [#SEC-6K-2026-05-07]

2026-09-30catalystLucid-MS IND filing and Phase 2 setupHigh impact

Quantum said it formally submitted an IND to the FDA for Lucid-MS, appointed a principal investigator, and signed a binding LOI with Allucent to conduct the planned Phase 2 MS trial. The May 7, 2026 release was also confirmed through the SEC-hosted Form 6-K exhibit, making this the clearest primary-source operating catalyst in the available evidence. [#PR-EARNINGS-2026-05-07] [#SEC-6K-2026-05-07]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-03 • Updated nightlySource: Internal modelMethodology